Free tool
Cell therapy stocks
We cover 1 company grouped under the Cell therapy theme. The median market value in the group is $355.75M. Across the group, the median move over the past trading day is +6.60%. Price change over the past year runs from +27.7% to +27.7% across the middle 80 percent of the group, with a median of +27.7%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
1 company of 86 matches these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| ALCLS.PA | Cellectis S.A. | $355.75M | Small cap | +27.74% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.